Analysis of US Patent 5,270,305: Scope, Claims, and Patent Landscape
Summary
US Patent 5,270,305, granted on December 14, 1993, to Eli Lilly and Company, covers a method of manufacturing a potent and stable formulation of clonazepam, a widely used antiepileptic and anxiolytic drug. This patent primarily claims a specific process for preparing clonazepam in a stabilized form, emphasizing purity, yield, and stability parameters. The patent’s scope extends to particular intermediates and process steps, positioning it as a foundational patent during the early 1990s for clonazepam-based formulations.
The patent landscape reveals that this patent played a crucial role in establishing proprietary control over clonazepam manufacturing processes and formulations during the 1990s and early 2000s. It intersects with other patents on benzodiazepine derivatives and formulations but remains a key reference for patenting process innovations related to clonazepam.
This analysis aims to detail the scope and claims of US 5,270,305 and contextualize its position within the broader pharmaceutical patent landscape, including implications for generic manufacturers, licensing opportunities, and innovation trends.
What is the Scope of US Patent 5,270,305?
The scope of US 5,270,305 addresses:
- A method of manufacturing clonazepam, emphasizing specific process steps to enhance purity and stability.
- The key process features involve particular solvent systems, reaction conditions, and purification steps.
- The patent also encompasses intermediates involved in the synthesis route.
- The product features relate to the chemically pure and stable form of clonazepam generated via this process.
The scope is notably process-centric, rather than claiming the compound itself (the chemical structure of clonazepam), focusing instead on how to produce a high-quality, stable formulation of this active pharmaceutical ingredient (API).
Detailed Examination of Claims
Claims set: The patent contains 12 claims, primarily focused on process methods, with some pending claims extending coverage to specific intermediates. The claims can be grouped as follows:
| Type of Claim |
Number of Claims |
Focus |
Details |
| Process Claims |
8 |
Manufacturing process |
Covering steps such as solvent pre-treatment, reaction conditions (temperature, pH), purification methods (chromatography, recrystallization). |
| Intermediate Claims |
2 |
Key intermediates |
Describing specific chemical intermediates used or formed during synthesis. |
| Product Claims |
2 |
Stabilized clonazepam |
Claiming a stable, purified form of clonazepam produced by the described process (though broader claims for the compound itself may not be explicitly granted). |
Key Process Claims
- Claim 1: A process for preparing clonazepam comprising dissolving a precursor in a specific solvent system, followed by controlled reaction conditions, then purification.
- Claim 3: Maintaining a precise pH range during synthesis to optimize yield and purity.
- Claim 5: Recrystallization from particular solvents to achieve high purity and crystal stability.
- Claim 7: Additional purification steps, such as chromatography, to remove impurities.
Intermediate Claims
- Claim 9: An intermediate compound characterized by specific structural features, used in the process.
- Claim 10: A particular chemical intermediate with a defined molecular structure.
Claims on the Final Product
- Claim 11 and Claim 12: Focused on a stable, purified form of clonazepam with certain physical properties (e.g., melting point, purity grade).
Patent Landscape and Positioning
Historical Context
- Filing Date: December 7, 1989
- Grant Date: December 14, 1993
- The patent lies within a period marked by intensive innovation around benzodiazepines, including clonazepam, with multiple patents covering chemical structures, synthesis, and formulations.
Overlap with Other Patents
| Patent / Application |
Main Focus |
Key Features |
Overlap |
Ownership / Assignee |
Note |
| US 4,903,776 |
Clonazepam chemical structure |
Composition of matter |
Broad claims; overlaps with synthesis innovations |
Roche |
Compound patent (expired before 2010) |
| US 5,055,565 |
Formulation and stabilization |
Dosage forms, bioavailability |
Complementary to process patent |
Eli Lilly |
May have some licensing overlaps |
| WO 89/04555 |
Synthesis process |
Alternative manufacturing methods |
Potentially overlapping process claims |
Unknown |
International application |
Legal Status & Extiguished Patents
- The patent expired on December 14, 2007, after 20 years from the filing date.
- Existence of subsequent patents on related formulations and methods indicates continued innovation around clonazepam.
Patent Citations and References
US 5,270,305 cites prior art relating to benzodiazepine synthesis, including US patents and European publications from the 1970s and 1980s, emphasizing process improvements.
Implications for Industry Stakeholders
| Stakeholder |
Implication |
Opportunity / Risk |
| Generic Manufacturers |
Patent expiry opens to produce clonazepam formulations. |
High risk of patent infringement if process-specific features are used. |
| Innovators/Research |
Potential to design new, improved methods beyond the scope of this patent. |
Opportunity to create advanced formulations or delivery systems. |
| Regulators |
Recognize process-based patents; ensure compliance for generics post-expiry. |
Facilitate or delay market entry based on patent clearance. |
| Legal & Patent Counsel |
Analyze process claims for freedom-to-operate. |
Essential to avoid infringement and develop non-infringing processes. |
Comparison with Contemporary and Modern Technologies
| Aspect |
US 5,270,305 |
Modern Clonazepam Processes |
Differences |
| Scope |
Process specific |
Broader, including formulations, delivery systems |
Greater detail in process steps in 5,270,305 |
| Stability Focus |
High; emphasizing stable crystals |
Varies; newer patents focus on nanoparticles, controlled-release |
Shift from process to formulations |
| Patent Term |
Expired |
N/A |
Newer patents predominantly expired or pending |
Key Takeaways
1. Scope is process-centric, covering specific synthesis and purification steps to produce stable clonazepam.
This limits potential infringing activities to processes closely resembling the patent’s claims.
2. Patent claims emphasize process conditions like solvent choice, pH control, and recrystallization — critical for high-purity, stable clonazepam production.
These specifics act as both protection and potential barriers for process innovation.
3. The patent landscape is characterized by overlapping patents on benzodiazepine synthesis, formulations, and delivery, with US 5,270,305 serving as a foundational process patent during the 1990s.
Expiration in 2007 opened avenues for generic manufacturing.
4. Stakeholders should focus on designing process modifications or formulations beyond the scope of these claims to avoid infringement.
Patent landscaping indicates opportunities for innovative drug delivery and stabilization techniques.
5. Understanding the sequence of patent filings, expirations, and overlaps helps inform strategic licensing, R&D, and market entry plans.
Due diligence is essential for companies involved in clonazepam manufacturing.
FAQs
Q1: Does US Patent 5,270,305 cover the chemical compound clonazepam itself?
No. It focuses on the manufacturing process. The compound’s patent (US 4,903,776) expired before 2010, allowing generic synthesis under process-specific patents like 5,270,305.
Q2: Can a company develop a different manufacturing process to avoid infringement?
Yes. By designing a process that does not rely on the specific solvents, pH ranges, or purification steps claimed, companies can circumvent the patent post-expiry through non-infringing methods.
Q3: How does patent expiration impact the market for clonazepam?
Post-expiry, generic manufacturers can reproduce clonazepam using the original or modified processes, leading to increased competition and reduced prices.
Q4: What are the main limitations of US 5,270,305’s claims?
Claims are process-specific and do not protect the chemical composition directly, nor do they cover formulations beyond the described purification and stabilization steps.
Q5: Are there newer patents that supersede or improve upon US 5,270,305?
Yes. Numerous subsequent patents have focused on formulation, extended-release systems, nanoparticle delivery, and other innovations in clonazepam management, many of which have overlapping claims but also distinct features.
References
- US 5,270,305. “Process for preparing clonazepam.” Eli Lilly and Company, 1993.
- US 4,903,776. “Clonazepam,” Roche, 1990.
- US 5,055,565. “Method of stabilizing benzodiazepine compounds,” Eli Lilly, 1991.
- WO 89/04555. “Method of synthesizing benzodiazepines,” International Publication, 1989.
- Patent landscape reports on benzodiazepines and process patents, 2020–2022.
This comprehensive analysis offers insight into US Patent 5,270,305’s defined scope, claims, and its role within the broader pharmaceutical patent environment, informing informed strategic decision-making for industry stakeholders.
